Inozyme Pharma Inc [INZY] stock is trading at $1.52, up 11.76%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The INZY shares have gain 12.59% over the last week, with a monthly amount drifted -48.12%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Inozyme Pharma Inc [NASDAQ: INZY] stock has seen the most recent analyst activity on December 12, 2024, when Raymond James initiated its Outperform rating and assigned the stock a price target of $26. Previously, Stifel started tracking the stock with Buy rating on September 12, 2024, and set its price target to $16. Wells Fargo started tracking the stock assigning a Overweight rating and suggested a price target of $14 on May 30, 2024. Jefferies upgraded its rating to a Buy and raised its price target to $6 on March 23, 2023. Jefferies started tracking with a Hold rating for this stock on May 26, 2022, and assigned it a price target of $5. In a note dated February 07, 2022, H.C. Wainwright initiated an Buy rating and provided a target price of $33 on this stock.
Inozyme Pharma Inc [INZY] stock has fluctuated between $1.24 and $7.80 over the past year. Currently, Wall Street analysts expect the stock to reach $16 within the next 12 months. Inozyme Pharma Inc [NASDAQ: INZY] shares were valued at $1.52 at the most recent close of the market. An investor can expect a potential return of 952.63% based on the average INZY price forecast.
Analyzing the INZY fundamentals
Gross Profit Margin for this corporation currently stands at 0.56% with Operating Profit Margin at -50.44%, Pretax Profit Margin comes in at -48.83%, and Net Profit Margin reading is -48.83%. To continue investigating profitability, this company’s Return on Assets is posted at -0.67, Equity is -0.88 and Total Capital is -0.8. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.57.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.4000 points at the first support level, and at 1.2800 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.5900, and for the 2nd resistance point, it is at 1.6600.
Ratios To Look Out For
For context, Inozyme Pharma Inc’s Current Ratio is 7.68. Further, the Quick Ratio stands at 7.68, while the Cash Ratio is 1.34.
Transactions by insiders
Recent insider trading involved Treco Douglas A, CEO, that happened on Apr 02 ’24 when 7523.0 shares were sold.
